Stay updated on Pembrolizumab for Leukoplakia Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Leukoplakia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Leukoplakia Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:36:39.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the clinical response rate at 6 months for the phase II pilot trial evaluating the efficacy of pembrolizumab in treating leukoplakia.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:12.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions based on factors like general health condition or prior treatments. This change provides more context and examples of what eligibility criteria entail.
    Difference
    51%
    Check dated 2024-05-22T21:25:09.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:53:31.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Leukoplakia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Leukoplakia Clinical Trial page.